Mave Health Raises $2.1M Seed for tDCS Focus and Stress Regulation Wearable
Summary
Mave Health has announced $2.1 million in seed funding led by Blume Ventures with participation from Stanford Angels, Dhaval Shroff, and Raymond Russell. The company has launched a non-invasive wearable headset using transcranial direct current stimulation to improve focus, elevate mood, and regulate stress in 20-minute daily sessions. The headset weighs 100 grams, lasts up to one month on a single charge, and does not collect brain data or require internet connectivity. Mave is available for pre-order at $495 with no subscription fees.
Why it matters
Mave Health's entry into the consumer tDCS market represents a significant milestone in making neuromodulation accessible outside clinical settings. With over 10,000 published papers on tDCS and an excellent safety profile, the technology has been waiting for a consumer-friendly form factor. By eliminating subscription fees and pricing the device at $495, Mave could drive broader adoption of neuromodulation for everyday cognitive enhancement and mental wellness. The funding demonstrates that even small rounds can support meaningful product launches in the direct-to-consumer neurotechnology space.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial